Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives
- K. Kalantzi, M. Tsoumani, I. Goudevenos, A. Tselepis
- Medicine
- Expert review of clinical pharmacology
- 1 May 2012
Platelets play an important role in atherothrombotic disease. The currently available antiplatelet drugs target key steps of platelet activation including thromboxane A2 synthesis, ADP-mediated… Expand
The Impact of Hemodialysis on the Dispersion of Ventricular Repolarization
- K. Kalantzi, C. Gouva, +6 authors P. Korantzopoulos
- Medicine
- Pacing and clinical electrophysiology : PACE
- 1 March 2013
Sudden cardiac death is prevalent in chronic hemodialysis (HD) patients while the dialysis process may have arrhythmogenic potential. We sought to examine the effect of HD on conventional… Expand
The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment
- K. Kalantzi, A. A. Dimitriou, J. Goudevenos, A. Tselepis
- Medicine
- Platelets
- 7 February 2012
Platelets are involved in thrombus formation and inflammation following vascular injury, while clopidogrel exerts antithrombotic and anti-inflammatory actions. We investigated various… Expand
The relative value of metabolic syndrome and cardiovascular risk score estimates in premature acute coronary syndromes.
- K. Kalantzi, P. Korantzopoulos, P. Tzimas, C. Katsouras, J. Goudevenos, H. Milionis
- Medicine
- American heart journal
- 1 March 2008
BACKGROUND
To compare the relative value of metabolic syndrome (MetS) and cardiovascular risk score estimates in patients with acute coronary syndromes (ACS) aged <45 years.
PATIENTS AND METHODS… Expand
Platelet-mediated inflammation in cardiovascular disease. Potential role of platelet-endothelium interactions.
- M. Tsoumani, K. Kalantzi, I. Goudevenos, A. Tselepis
- Medicine
- Current vascular pharmacology
- 31 August 2012
Inflammation of the vascular wall is considered as the principal underlying mechanism in the development of atherosclerosis. Besides their specific functions in haemostasis via thrombus formation… Expand
Clopidogrel differentially affects platelet‐mediated thrombosis and inflammatory response in patients with acute coronary syndromes
- K. Kalantzi, A. A. Dimitriou, H. Milionis, I. Goudevenos, A. Tselepis
- Medicine
- Journal of thrombosis and haemostasis : JTH
- 1 April 2011
1 Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8–13. 2 Grundy SM, Howard B, Smith S, Eckel R, Redberg R, Bonow RO. Prevention Conference… Expand
Antiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome
- M. Tsoumani, K. Kalantzi, A. A. Dimitriou, I. Ntalas, I. Goudevenos, A. Tselepis
- Medicine
- Angiology
- 1 October 2012
The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. We compared the antiplatelet… Expand
Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate
- M. Tsoumani, K. Kalantzi, A. A. Dimitriou, I. Ntalas, I. Goudevenos, A. Tselepis
- Medicine
- Expert opinion on pharmacotherapy
- 14 January 2012
Objective: The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. In this study we… Expand
Clopidogrel generic formulations in the era of new antiplatelets: a systematic review.
- M. Tsoumani, K. Kalantzi, I. Goudevenos, A. Tselepis
- Medicine
- Current vascular pharmacology
- 24 July 2013
Clopidogrel is a thienopyridine that selectively and irreversibly inhibits the ADP purinergic receptor P2Y12 and the subsequent ADP-mediated platelet activation. Clopidogrel has been approved for… Expand
Antiplatelet Treatment in the Secondary Prevention of Coronary and Cerebrovascular Disease
- I. Ntalas, H. Milionis, A. Kei, K. Kalantzi, J. Goudevenos
- Medicine
- Angiology
- 1 July 2014
Ischemic heart disease and cerebrovascular disease remain major health problems with associated mortality and quality-of-life consequences. Antiplatelet agents, including thienopyridines and the new… Expand
...
1
2
...